Filter

Refine by collections

Refine by date

—
  • Print
  • Save

Search Results

You are looking at 1 - 3 of 3 items for :

Clear All
Giulia Bresciani Section of Endocrinology and Internal Medicine, Department of Medical Sciences, University of Ferrara, Ferrara, Italy

Search for other papers by Giulia Bresciani in
Google Scholar
PubMed Close
,
Angeliki Ditsiou Department of Biochemistry and Biomedicine, School of Life Sciences, University of Sussex, Brighton, UK

Search for other papers by Angeliki Ditsiou in
Google Scholar
PubMed Close
,
Chiara Cilibrasi Department of Biochemistry and Biomedicine, School of Life Sciences, University of Sussex, Brighton, UK

Search for other papers by Chiara Cilibrasi in
Google Scholar
PubMed Close
,
Viviana Vella Department of Biochemistry and Biomedicine, School of Life Sciences, University of Sussex, Brighton, UK

Search for other papers by Viviana Vella in
Google Scholar
PubMed Close
,
Federico Rea Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Padua, Italy

Search for other papers by Federico Rea in
Google Scholar
PubMed Close
,
Marco Schiavon Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Padua, Italy

Search for other papers by Marco Schiavon in
Google Scholar
PubMed Close
,
Narciso Giorgio Cavallesco Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy

Search for other papers by Narciso Giorgio Cavallesco in
Google Scholar
PubMed Close
,
Georgios Giamas Department of Biochemistry and Biomedicine, School of Life Sciences, University of Sussex, Brighton, UK

Search for other papers by Georgios Giamas in
Google Scholar
PubMed Close
,
Maria Chiara Zatelli Section of Endocrinology and Internal Medicine, Department of Medical Sciences, University of Ferrara, Ferrara, Italy

Search for other papers by Maria Chiara Zatelli in
Google Scholar
PubMed Close
, and
Teresa Gagliano Department of Biochemistry and Biomedicine, School of Life Sciences, University of Sussex, Brighton, UK

Search for other papers by Teresa Gagliano in
Google Scholar
PubMed Close

therapeutic targets in the treatment of BP-NENs. Moreover, we have also assessed whether other RTK inhibitors, erlotinib and linsitinib, could be effective in malignancy management. Materials and methods Drugs and chemicals Sunitinib, erlotinib and

Article Type:
Research Article
DOI:
https://doi.org/10.1530/EC-19-0192
Volume/Issue:
Volume 8: Issue 6
Open access
Maria Cristina De Martino Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
Dipartimento di Medicina Clinica e Chirurgia, Università Federico II, Naples, Italy

Search for other papers by Maria Cristina De Martino in
Google Scholar
PubMed Close
,
Richard A Feelders Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands

Search for other papers by Richard A Feelders in
Google Scholar
PubMed Close
,
Claudia Pivonello Dipartimento di Medicina Clinica e Chirurgia, Università Federico II, Naples, Italy

Search for other papers by Claudia Pivonello in
Google Scholar
PubMed Close
,
Chiara Simeoli Dipartimento di Medicina Clinica e Chirurgia, Università Federico II, Naples, Italy

Search for other papers by Chiara Simeoli in
Google Scholar
PubMed Close
,
Fortuna Papa Dipartimento di Medicina Clinica e Chirurgia, Università Federico II, Naples, Italy

Search for other papers by Fortuna Papa in
Google Scholar
PubMed Close
,
Annamaria Colao Dipartimento di Medicina Clinica e Chirurgia, Università Federico II, Naples, Italy

Search for other papers by Annamaria Colao in
Google Scholar
PubMed Close
,
Rosario Pivonello Dipartimento di Medicina Clinica e Chirurgia, Università Federico II, Naples, Italy

Search for other papers by Rosario Pivonello in
Google Scholar
PubMed Close
, and
Leo J Hofland Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands

Search for other papers by Leo J Hofland in
Google Scholar
PubMed Close

Sirolumus and everolimus inhibited cell proliferation in H295R and HAC15 cells in a dose dependent manner Linsitinib DNA measurement Selected doses of sirolimus or everolimus combined with linsitinib 5 × 10 −8  M had statistically significant additive

Article Type:
Review Article
DOI:
https://doi.org/10.1530/EC-19-0224
Volume/Issue:
Volume 8: Issue 9
Open access
Emily Warmington Institute of Metabolism and System Research, University of Birmingham, Birmingham, UK

Search for other papers by Emily Warmington in
Google Scholar
PubMed Close
,
Gabrielle Smith Institute of Metabolism and System Research, University of Birmingham, Birmingham, UK

Search for other papers by Gabrielle Smith in
Google Scholar
PubMed Close
,
Vasileios Chortis Institute of Metabolism and System Research, University of Birmingham, Birmingham, UK

Search for other papers by Vasileios Chortis in
Google Scholar
PubMed Close
,
Raimunde Liang Division of Endocrinology and Diabetes, University Hospital of Wuerzburg, Wuerzburg, Germany
Department of Neurosurgery, Technical University Munich (TMU), Munich, Germany

Search for other papers by Raimunde Liang in
Google Scholar
PubMed Close
,
Juliane Lippert Division of Endocrinology and Diabetes, University Hospital of Wuerzburg, Wuerzburg, Germany

Search for other papers by Juliane Lippert in
Google Scholar
PubMed Close
,
Sonja Steinhauer Division of Endocrinology and Diabetes, University Hospital of Wuerzburg, Wuerzburg, Germany

Search for other papers by Sonja Steinhauer in
Google Scholar
PubMed Close
,
Laura-Sophie Landwehr Division of Endocrinology and Diabetes, University Hospital of Wuerzburg, Wuerzburg, Germany

Search for other papers by Laura-Sophie Landwehr in
Google Scholar
PubMed Close
,
Constanze Hantel Department of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Zurich (USZ) and University of Zurich (UZH), Zurich, Switzerland
Medizinische Klinik Und Poliklinik III, University Hospital Carl Gustav Carus, Dresden, Germany

Search for other papers by Constanze Hantel in
Google Scholar
PubMed Close
,
Katja Kiseljak-Vassiliades Division of Endocrinology Metabolism and Diabetes, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA

Search for other papers by Katja Kiseljak-Vassiliades in
Google Scholar
PubMed Close
,
Margaret E Wierman Division of Endocrinology Metabolism and Diabetes, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA

Search for other papers by Margaret E Wierman in
Google Scholar
PubMed Close
,
Barbara Altieri Division of Endocrinology and Diabetes, University Hospital of Wuerzburg, Wuerzburg, Germany

Search for other papers by Barbara Altieri in
Google Scholar
PubMed Close
,
Paul A Foster Institute of Metabolism and System Research, University of Birmingham, Birmingham, UK
Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, Birmingham, UK

Search for other papers by Paul A Foster in
Google Scholar
PubMed Close
, and
Cristina L Ronchi Institute of Metabolism and System Research, University of Birmingham, Birmingham, UK
Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, Birmingham, UK

Search for other papers by Cristina L Ronchi in
Google Scholar
PubMed Close

. Nevertheless, results have been largely unsatisfactory (reviewed in ( 10 , 11 )). Linsitinib, a dual inhibitor of the insulin-like growth factor 1 receptor (IGF1R) and insulin receptor (IR), is the only targeted drug to have entered a phase III trial for ACC

Article Type:
Research Article
Collections:
Adrenal
DOI:
https://doi.org/10.1530/EC-23-0403
Volume/Issue:
Volume 13: Issue 1
Open access